Oncolytics Biotech Inc has been granted US Patent 7,429,485 entitled 'Method of Producing Infectious Reovirus'. The claims cover methods of purifying reassorted reovirus from an FDA-approved cell line.

"This patent provides broad protection for methods of producing reassorted reovirus," said Mary Ann Dillahunty, vice president of Intellectual Property for Oncolytics. "It expands our already substantial portfolio of patents which cover the production of therapeutic reovirus."

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.